While the concept of targeting APBs is promising, it comes with several challenges. One major hurdle is the potential for toxicity in normal cells that might also utilize components of the ALT pathway under certain conditions, such as during cellular stress or in specific tissues. Additionally, the redundancy and adaptability of cancer cells mean that they could potentially find alternative ways to maintain their telomeres, even if APBs are disrupted. Therefore, a comprehensive understanding of the molecular mechanisms governing APBs is essential for developing effective and specific therapies.
